Reading the tape
NYSE: CRL
Charles River Laboratories International, Inc.
Healthcare · Medical - Diagnostics & Research
Market Cap
$8.63B
52w High
$228.88
52w Low
$113.89
P/E
-59.62
Volume
9.22K
Outstanding Shares
49.34M
Price vs Fundamentals
Why The Stock Is Moving
Fundamentals are supporting the moveModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 44.27%Revenue (TTM): -0.85%FCF (TTM): 3.37%P/FCF: 15th pct
What changed
The stock rose 44.27% over the last year. Revenue declined 0.85% over the trailing twelve months. Operating margin moved from 5.61% to 10.68%. Free cash flow grew 3.37% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum, and the shares are still only around the 15th percentile of their historical P/FCF range.
What would invalidate this read
Operating margin is at 10.68%. Revenue declined 0.85% — this thesis depends on that trajectory holding. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
CEOJames C. Foster
SectorHealthcare
IndustryMedical - Diagnostics & Research
Employees18,700
IPO dateJun 23, 2000
Valuation
Forward P/E—
EV/EBITDA14.21
Enterprise value$12.95B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth-0.83%
Gross margin32.91%▼7.18%vs FY2024
Operating margin10.68%▲125.30%vs FY2024
ROE-4.56%▼1633.25%vs FY2024
Analyst consensus
RatingBuy
Target price$205.43▲17.49%
25
Buy
11
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est $1.96 · Revenue est $977.46M
View